MEI Pharma, Inc. (MEIP) said Friday that it has priced an underwritten public offering of 10 million shares of its common stock at an offering price of $4.00 per share, for total gross proceeds, before underwriting discount and commissions and estimated expenses, of about $40 million.
The company has granted the underwriters a 30-day option to purchase up to 1.5 million additional shares of its common stock.
The offering is expected to close on December 17.
The company plans to use the net proceeds of the offering, together with other available funds, to progress the clinical development programs for Pracinostat in acute myeloid leukemia and for other general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.